Santhera's Vamorolone Shows Long-Term Safety Edge in Duchenne Muscular Dystrophy
Event summary
- Santhera presented long-term data at MDA 2026 showing vamorolone's effectiveness comparable to corticosteroids over up to 8 years.
- Vamorolone demonstrated 80% fewer vertebral fractures (8.1% vs 41.9% on deflazacort) and maintained normal height with a 12.17 cm advantage.
- Cataracts occurred in 5.3% of vamorolone patients vs 37.8% on deflazacort, with no glaucoma cases observed.
- The ongoing GUARDIAN study will continue assessing long-term outcomes including muscle function, bone health, and safety.
The big picture
Santhera's data reinforces vamorolone's position as a next-generation corticosteroid alternative, addressing critical safety concerns that limit long-term use of traditional therapies. The findings come as the Duchenne treatment landscape evolves toward combination approaches, where vamorolone's favorable profile could provide a competitive advantage. With partnerships spanning multiple regions, Santhera is positioning the drug for broader global adoption.
What we're watching
- Therapeutic Differentiation
- Whether vamorolone's safety profile can position it as a preferred alternative to traditional corticosteroids in Duchenne treatment.
- Combination Therapy Potential
- How vamorolone's tolerability may enhance its use alongside emerging Duchenne therapies.
- Regulatory Expansion
- The pace at which Santhera can secure additional approvals for vamorolone in new markets.
Related topics